Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma

Fig. 2

SF3B1 is elevated in HCC tissues of HCC-model mice and human HCC patients. a Western blot analysis of SF3B1 expression in H-ras12V transgenic HCC model mice. Liver tissues of three normal mice and six H-ras12V-Tg mice were homogenized, lysed in RIPA buffer, and resolved by 10% SDS-PAGE/western blotting. Band intensities on the western blot were quantified by Image J and normalized to that of β-actin; b Representative immunohistochemical staining with anti-SF3B1 antibody in liver tissues of HCC model transgenic mice (HBx-Tg and H-ras12V-Tg; T, tumor; NT, non-tumor region; ST, small tumor; LT, large tumor). DAB intensities of IHC staining (Additional file 4: Fig. S3) were quantified by Image J and plotted; c Analysis of SF3B1 mRNA expression in human normal liver and liver cancer using GENT database (http://medicalgenome.kribb.re.kr/GENT/); d Western blot analysis of SF3B1 in exosomes from HepG2 or Huh7 cell cultured media using anti-SF3B1 antibody or XC24 autoantibody. As subcellular fraction markers, ALIX (exosome marker) and calnexin (ER marker to examine cell contamination) were also probed. The amount of protein loaded in each lane is 5ug. Lys: cell lysate, Exo: exosome lysate

Back to article page